Shares of Niagen Bioscience (NASDAQ: NAGE) soared 22.45% in after-hours trading on Wednesday, following the release of its second-quarter 2025 financial results that significantly exceeded analyst expectations. The company, known for its innovative bioscience products, not only beat earnings estimates but also raised its full-year outlook, sparking investor enthusiasm.
Niagen Bioscience reported quarterly earnings of $0.04 per share, doubling the analyst consensus estimate of $0.02. The company's Q2 sales reached $31.117 million, surpassing the projected $28.324 million by 9.86%. Notably, this represents a robust 36.84% increase compared to the $22.739 million in sales reported for the same period last year. The strong performance was further underscored by a gross profit of $20.226 million and an operating income of $3.185 million for the quarter.
Adding to the positive sentiment, Niagen Bioscience announced an increase in its full-year outlook, although specific details were not immediately available. This optimistic forward guidance, coupled with the company's ability to outperform in a challenging economic environment, likely contributed to the significant after-hours stock rally. Investors and analysts will be keenly watching for further details on the company's growth strategy and the factors behind its raised expectations for the remainder of the year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.